Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;14(24):2473-2483.
doi: 10.1111/1759-7714.15032. Epub 2023 Jul 13.

Assessing the role of colonic and other anatomical sites uptake by [18 F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors

Affiliations

Assessing the role of colonic and other anatomical sites uptake by [18 F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors

Alessio Rizzo et al. Thorac Cancer. 2023 Aug.

Abstract

Background: Inflammation in non-small cell lung cancer (NSCLC) may impair the response to immune checkpoint inhibitors (ICIs) and can be indicated by peripheral blood inflammatory indexes. 2-deoxy-2-[18 F]fluoro-D-glucose positron emission tomography/computed tomography ([18 F] FDG-PET/CT) may be used as a marker of inflammation by measuring glucose metabolism in different colonic sites.

Methods: This retrospective analysis aimed to investigate the correlation between [18 F] FDGPET/CT SUVratio in six gastrointestinal districts, the spleen, the pharynx and the larynx alongside the most avid tumor lesion with peripheral blood inflammatory indexes, including the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammatory index (SII, i.e., NLR times platelets) and lactate dehydrogenase (LDH), in patients with [18 F] FDG-PET/CT staged IV NSCLC who received first-line immune checkpoint inhibitors (ICIs). The role of SUVratios and peripheral blood inflammatory indexes in predicting overall survival (OS) and progression-free survival (PFS) was then explored.

Results: A total of 43 patients were treated with first-line ICI alone (58%) or in combination with chemotherapy (42%). A significant correlation was only found between the rectosigmoid SUVratio and NLR (p = 0.0465). NLR >5.5 and LDH > 333.5 were associated with a worse OS (p = 0.033 and p = 0.009, respectively). The SII was associated with a worse PFS in patients treated with ICI alone (p = 0.033). None of the SUVratios were significantly associated with OS or PFS, although a high left colon SUVratio showed a trend toward a worse PFS.

Conclusion: There was no significant correlation between [18 F]FDG PET/CT uptake in different anatomical sites, and in the tumor, and systemic immune-inflammatory indexes. The prognostic role of high left colon SUVratio deserves further investigation.

Keywords: NLR; gut microbiome; immune checkpoint inhibitor; immunotherapy; lung cancer.

PubMed Disclaimer

Conflict of interest statement

Giuseppe Luigi Banna reports personal fees from AstraZeneca, Astellas, travel and conference expenses from Janssen, outside the submitted work. Vanesa Gregorc declared consultant/advisor's fees from Boehringer Ingelheim, Bistol Myear Squibb, and Janssen outside the submitted work. Silvia Novello declared speaker bureau/advisor's fee from Eli Lilly, MSD, Roche, Bristol Myer Squibb, Amgen, Takeda, Pfizer, Thermo Fisher Scientific, Astra Zeneca and Boehringer Ingelheim outside the submitted work. The other authors have nothing to declare.

Figures

FIGURE 1
FIGURE 1
Example of transverse colon manual contouring on transaxial positron emission tomography/computed tomography (PET/CT) fused images., ,
FIGURE 2
FIGURE 2
Kaplan–Meier from univariable Cox regression model on OS (1, 2, 3) and on PFS (4, 5, 6) according to receiver operating characteristic (ROC) curve‐based cutoff. CI‐L, confidence interval‐lower; CI‐U, confidence interval‐upper; No., number; NLR, neutrophil‐to‐lymphocyte ratio; OS, overall survival; PFS, progression‐free survival; SII, systemic immune‐inflammatory index.

Similar articles

Cited by

References

    1. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535–554. 10.1016/S0140-6736(21)00312-3 - DOI - PubMed
    1. Cvetkovic L, Régis C, Richard C, Derosa L, Leblond A, Malo J, et al. Physiologic colonic uptake of 18F‐FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2021;48(5):1550–1559. 10.1007/s00259-020-05081-6 - DOI - PubMed
    1. Oh B, Boyle F, Pavlakis N, Clarke S, Eade T, Hruby G, et al. The gut microbiome and cancer immunotherapy: can we use the gut microbiome as a predictive biomarker for clinical response in cancer immunotherapy? Cancer. 2021;13(19):4824. 10.3390/cancers13194824 - DOI - PMC - PubMed
    1. Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non‐small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25(15):4592–4602. 10.1158/1078-0432.CCR-18-1538 - DOI - PMC - PubMed
    1. Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, et al. Immune‐checkpoint inhibitors in non‐small cell lung cancer: a tool to improve patients' selection. Crit Rev Oncol Hematol. 2018;129:27–39. 10.1016/j.critrevonc.2018.06.016 - DOI - PubMed

Publication types

MeSH terms

Substances